Despite challenges in standardization and further research requirements, PET-PSMA imaging represents a significant advancement in prostate cancer management, offering superior diagnostic capabilities and invaluable insights into treatment response dynamics, ultimately leading to improved patient outcomes and quality of life. This evidence concerns the gene FOLH1 and prostate cancer.